CYTK Cytokinetics Inc
Price (delayed)
$40.25
Market cap
$4.77B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.26
Enterprise value
$5.46B
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by
Highlights
Cytokinetics's gross profit has soared by 145% YoY
The revenue has soared by 145% year-on-year
Cytokinetics's quick ratio has decreased by 34% from the previous quarter
The net income is down by 12% year-on-year and by 2.3% since the previous quarter
Key stats
What are the main financial stats of CYTK
Market
Valuations
Earnings
Shares outstanding
118.41M
Market cap
$4.77B
Enterprise value
$5.46B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
243.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.54
Revenue
$18.47M
Gross profit
$18.47M
Operating income
-$536.25M
Net income
-$589.53M
EBIT
-$551.83M
EBITDA
-$542.29M
Free cash flow
-$399.8M
Per share
Balance sheet
Liquidity
EPS
-$5.26
EPS diluted
-$5.26
Free cash flow per share
-$3.57
Book value per share
-$1.15
Revenue per share
$0.16
TBVPS
$12.52
Total assets
$1.4B
Total liabilities
$1.54B
Debt
$788.68M
Equity
-$135.37M
Working capital
$928.27M
Debt to equity
-5.83
Current ratio
6.17
Quick ratio
6.08
Net debt/EBITDA
-1.28
Margins
Efficiency
Dividend
EBITDA margin
-2,935.4%
Gross margin
100%
Net margin
-3,191.1%
Operating margin
-2,902.7%
Return on assets
-45.6%
Return on equity
N/A
Return on invested capital
-30%
Return on capital employed
-45.2%
Return on sales
-2,987%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYTK stock price
How has the Cytokinetics stock price performed over time
Intraday
7.33%
1 week
-7.75%
1 month
-12.5%
1 year
-43.29%
YTD
-14.43%
QTD
0.15%
Financial performance
How have Cytokinetics's revenue and profit performed over time
Revenue
$18.47M
Gross profit
$18.47M
Operating income
-$536.25M
Net income
-$589.53M
Gross margin
100%
Net margin
-3,191.1%
Cytokinetics's gross profit has soared by 145% YoY
The revenue has soared by 145% year-on-year
The net margin has soared by 82% from the previous quarter and by 54% YoY
Cytokinetics's operating margin has soared by 82% from the previous quarter and by 56% YoY
Growth
What is Cytokinetics's growth rate over time
Valuation
What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
243.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.54
The EPS has grown by 3.5% YoY and by 2.2% from the previous quarter
CYTK's equity has surged by 65% year-on-year
The revenue has soared by 145% year-on-year
CYTK's P/S is 85% below its last 4 quarters average of 1502.1 and 48% below its 5-year quarterly average of 436.6
Efficiency
How efficient is Cytokinetics business performance
The ROS has soared by 82% from the previous quarter and by 55% YoY
The company's return on assets rose by 30% YoY and by 9% QoQ
CYTK's return on invested capital is up by 17% year-on-year and by 6% since the previous quarter
Dividends
What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYTK.
Financial health
How did Cytokinetics financials performed over time
The total assets is 9% smaller than the total liabilities
The total assets has surged by 70% year-on-year but it has declined by 2.4% since the previous quarter
The company's current ratio fell by 34% QoQ
Cytokinetics's debt to equity has shrunk by 197% YoY but it has surged by 90% QoQ
CYTK's equity has surged by 65% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.